Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1990-10-5
|
pubmed:abstractText |
Recently it has been recognized that IL-1 plays an important role in hematopoietic regulation. Administration of 5-fluorouracil (5-FU) to mice causes prolonged neutropenia. rHIL-1 injected to mice after 5-FU, accelerated the recovery of hematopoietic progenitors and blood neutrophils. The combination of rhIL-1 and rhG-CSF reduced the neutropenic period significantly. Sublethal irradiation of mice induced profound neutropenia for 3 weeks which was associated with 80% mortality. Administration of rhIL-1 20 hours prior to or 2 hours post irradiation resulted in a significantly improved survival and rapid recovery of the neutrophil count. IL-1 administered alone or in combination with other colony stimulating factors to spontaneous breast tumor bearing mice following 5-FU therapy resulted in a rapid recovery of neutrophils, improved survival, and markedly reduced the tumor mass. Experiments in primates demonstrated that rhIL-1 administered to 5-FU treated animals shortened the neutropenic period from 30 to 17 days and increased the number of marrow progenitors responsive to other CSFs. Prolonged administration of IL-1 (14 days) to these animals resulted in a delayed neutrophil recovery as compared to animals receiving short courses of IL-1. rhIL-1 administered to primates receiving marrow grafts after lethal irradiation, did not result in rapid hematopoietic recovery. In humans, studies with CD-34 positive marrow cells showed that IL-1 had a radioprotective effect on a committed and early marrow progenitors. These data show the therapeutic potential of IL-1 in the treatment of chemoradiotherapy induced myelosuppression.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0921-299X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
293-300
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2484306-Animals,
pubmed-meshheading:2484306-Antigens, CD34,
pubmed-meshheading:2484306-Antigens, Differentiation,
pubmed-meshheading:2484306-Bone Marrow,
pubmed-meshheading:2484306-Bone Marrow Cells,
pubmed-meshheading:2484306-Combined Modality Therapy,
pubmed-meshheading:2484306-Drug Therapy,
pubmed-meshheading:2484306-Fluorouracil,
pubmed-meshheading:2484306-Hematopoietic Stem Cells,
pubmed-meshheading:2484306-Humans,
pubmed-meshheading:2484306-Interleukin-1,
pubmed-meshheading:2484306-Macaca fascicularis,
pubmed-meshheading:2484306-Mice,
pubmed-meshheading:2484306-Mice, Inbred BALB C,
pubmed-meshheading:2484306-Mice, Inbred Strains,
pubmed-meshheading:2484306-Neutropenia,
pubmed-meshheading:2484306-Radiotherapy
|
pubmed:year |
1989
|
pubmed:articleTitle |
Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy.
|
pubmed:affiliation |
Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|